Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2021: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2020: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
Outline of Final Research Achievements |
We reported the results of several studies using large databases: 1) In patients with HFpEF, nitrate use is inversely and significantly associated with increased risk of cardiovascular events (Tsujimoto et al. Mayo Clin Proc 2018), 2) No benefit of aspirin was found in type 2 diabetes patients with pre-existing cardiovascular disease using non-steroidal anti-inflammatory drugs (Tsujimoto et al. Diabetes Obes Metab 2019), 3) Thiazide may increase cardiovascular risk in type 2 diabetes patients with relatively low blood pressure (Tsujimoto et al. Hypertension 2019).
|